Our company is led by Leanne Labriola, DO, MBA, an ophthalmologist, and Dipanjan Pan, PhD, a professor in bioengineering. Our goal is to pursue ideas that can be translated from lab to clinic.


2018 Entrepreneurial Excellence: New Venture Award Finalist Formed in the last three years, and demonstrates a commitment to continuing success through entrepreneurial talent, creativity and energy. What can you learn from a drop of tears?



Our Team

Our company was founded in 2014. The company is comprised of engineers, ophthalmologists and business experts who are focused on delivering technology from the lab to the clinics to improve ocular care.


dipanjan pan, phd

Dr. Pan is a Fellow of Royal Society of Chemistry, the Director of Masters in Engineering Bioinstrumentation and is an Assistant Professor in the Department of Bioengineering, Materials Science and Engineering, Beckman Institute and Institute of Sustainability in Energy and Environment at the University of Illinois, Urbana-Champaign. He serves as Editor with Nature’s Scientific Reports. He has authored over 90 original publications, numerous abstracts, and patents in the area of materials science and nanomedicine.  His research is externally funded through the NIH, NSF, American Heart Association, and other organizations. He is the founder for three University-based start-ups- KaloCyte Inc., Vitruvian Biotech and InnSight Tech with demonstrated track record of translation. Dr. Pan has extensive expertise in chemistry, nanotechnology, materials science.


leanne labriola, do, MBA

Dr. Labriola is a board certified ophthalmologist at Carle Foundation Hospital in Urbana, Illinois with an appointment at the University of Illinois, Urbana-Champaign. She is a graduate of Duke University, the Philadelphia College of Osteopathic Medicine,  the University of Pittsburgh Ophthalmology Residency and the University of Southern California Retina Fellowship Programs. She also has an MBA in healthcare and pharmaceutical marketing from Haub Business School in Philadelphia. She has experience in clinical and bench research. She has practiced in systems within major academic centers as well as private hospitals. Her previous work for an algorithm for non-traumatic red eyes was awarded first place at the Emergency Medicine Scientific Seminar in Boston, MA. She started the ophthalmology clinical research program at Carle, which has over 10 sponsored national clinical trials that are meeting enrollment expectations. Her research is funded through the NSF and private grants and is focused on novel diagnostic methods. 


NIvetha Gunaseelan, MS

R&D Engineer


Will Streyer, PhD

Senior R&D Engineer


About InnSight Technology, Inc


Our company is dedicated to translational research initiatives that will advance diagnostics and evaluation of eye disease. Our primary focus is on the development and commercialization of the OcuCheck biosensor that is a novel, hand-held, point-of-service device for detection of anterior ophthalmic injuries.


Company Resources

Company Resources